Lexicon Pharmaceuticals, Inc. (LXRX)

NASDAQ: LXRX · Real-Time Price · USD

Compare

1.180

-0.090 (-7.09%)

At close: Feb 5, 2026, 4:00 PM EST

1.220

+0.040 (3.39%)

Pre-market: Feb 6, 2026, 6:12 AM EST

Lexicon Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	70.86	31.08	1.2	0.14	0.3	24
Revenue Growth (YoY)	1255.21%	2481.48%	766.19%	-53.36%	-98.76%	-92.55%
Cost of Revenue	75.81	84	58.97	52.52	55.05	153.05
Gross Profit	-4.95	-52.92	-57.77	-52.38	-54.75	-129.06
Selling, General & Admin	49.62	131.9	112.54	48.08	32.34	44.23
Operating Expenses	49.62	131.9	112.54	48.08	32.34	44.23
Operating Income	-54.57	-184.82	-170.31	-100.46	-87.09	-173.29
Interest Expense	-10.17	-15.58	-13.1	-2.78	-0.8	-14.54
Interest & Investment Income	8.46	12.29	7.73	1.6	0.13	2.77
EBT Excluding Unusual Items	-56.28	-188.1	-175.68	-101.64	-87.76	-185.06
Merger & Restructuring Charges	-	-	-	-	-	-5.5
Gain (Loss) on Sale of Assets	-	-	-	-	-	132.59
Asset Writedown	-	-	-	-	-	-1.6
Other Unusual Items	-12.3	-12.3	-1.44	-0.3	-	1
Pretax Income	-68.58	-200.4	-177.12	-101.94	-87.76	-58.57
Net Income	-68.58	-200.4	-177.12	-101.94	-87.76	-58.57
Net Income to Common	-68.58	-200.4	-177.12	-101.94	-87.76	-58.57
Shares Outstanding (Basic)	363	320	221	166	146	111
Shares Outstanding (Diluted)	363	320	221	166	146	111
Shares Change (YoY)	24.67%	44.73%	33.42%	13.79%	31.41%	-5.06%
EPS (Basic)	-0.19	-0.63	-0.80	-0.62	-0.60	-0.53
EPS (Diluted)	-0.19	-0.63	-0.80	-0.62	-0.60	-0.53
Free Cash Flow	-72.58	-179.81	-162.37	-90.18	-88.24	-143.06
Free Cash Flow Per Share	-0.20	-0.56	-0.73	-0.54	-0.61	-1.29
Gross Margin	-6.98%	-170.25%	-	-	-	-
Operating Margin	-77.00%	-594.63%	-14145.35%	-72273.38%	-29224.83%	-722.17%
Profit Margin	-96.77%	-644.78%	-14710.88%	-73341.01%	-29448.99%	-244.11%
Free Cash Flow Margin	-102.43%	-578.52%	-13485.63%	-64875.54%	-29610.07%	-596.19%
EBITDA	-53.94	-184.28	-169.76	-100.03	-86.8	-170.35
EBITDA Margin	-76.12%	-	-	-	-	-
D&A For EBITDA	0.63	0.53	0.55	0.43	0.29	2.93
EBIT	-54.57	-184.82	-170.31	-100.46	-87.09	-173.29
EBIT Margin	-77.00%	-	-	-	-	-
Revenue as Reported	70.86	31.08	1.2	0.14	0.3	24

Updated Nov 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q